Sign in
Taking people in FrancePhase 2

Momelotinib tested in VEXAS syndrome, with or without myelodysplastic syndrome

Tests momelotinib in adults with VEXAS syndrome who depend on or resist steroids.

Key facts

Who runs it
Groupe Francophone Des Myelodysplasies
Where
Angers, Clermont-Ferrand, Grenoble Cedex 9, Lille, Lorient, Nantes, Paris, Paris Cedex 12, Pessac, Pierre-Bénite, Rennes Cedex 9, Toulouse, and Tours Cedex 9, FranceSee the 13 sites
Registry title
Momelotinib in VEXAS syndrome
Status
Recruiting
Phase
Phase 2
People taking part
57 people, planned
Started
25 Nov 2025
Expected to end
1 Sept 2029
Type of study
Interventional
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with VEXAS syndrome and a UBA1 gene change. They must still have symptoms and need steroids despite earlier treatment.

Age
18 years or older
Sex
Women and men can join
Disease stage
VEXAS syndrome with symptoms that are not controlled, needing more than 10 mg/day of prednisone or equivalent. The syndrome can occur with or without myelodysplastic syndrome (MDS). People refractory/dependent to steroids can join.
Earlier treatment
Must have had at least one earlier treatment, including steroids. Only one steroid at a time is allowed. Other immune-lowering drugs need a 28-day break before starting. No erythropoietin or luspatercept in the 28 days before joining. People who have had JAK inhibitors cannot join.
Biomarker or test result
UBA1 gene mutation

Main reasons for not taking part

  • MDS planned for a stem cell transplant, or high-risk MDS
  • Earlier treatment with JAK inhibitors
  • Another active cancer, with a few exceptions
  • Active infection needing treatment, or known HIV, hepatitis B or hepatitis C infection
  • Severe heart problems or a stroke or blood clot in the lung within 12 weeks before starting

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • ECOG performance status 0-2 at the time of screening
  • Adequate liver function (serum transaminases ≤ 3N, Bilirubin ≤ 1.5 x ULN (isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%))
  • Adequate renal function (creatinine clearance with MDRD formula > 30 ml/min)
  • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must: 1- Have a negative serum or urine pregnancy test within 24-hours prior to beginning treatment on this study. Lactating patients are excluded. 2- Agree to use, and to be able to comply with, effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy (including doses interruptions) and for 12 weeks after the end of the study drug therapy. 3- Agree to learn about the procedures for preservation of egg before starting treatment
  • Male patients must: 1- Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential during the entire period of treatment, even if disruption of treatment and during 12 weeks after end of treatment. 2- Agree to learn about the procedures for preservation of sperm before starting treatment
  • Age ≥ 18 years
  • Written informed consent
  • Diagnosis of VEXAS syndrome with UBA1 mutation and clinically symptomatic disease requiring corticosteroid therapy with more than 10 mg/day of prednisone equivalent
  • With uncontrolled symptoms related to VEXAS with prior treatment line(s) (including steroids)
  • Patients refractory/dependent to steroids
  • Single concomitant steroids therapy (e.g. prednisone or equivalent) at the time of inclusion is allowed
  • For patients treated with other immunosuppressive/immuno-modulatory therapy than glucocorticoids, a wash out period of 28 days is required prior MMB onset
  • Erythropoietin/luspatercept used as a growth factor is not allowed 28 days prior enrollment

Who cannot take part

  • Patients with MDS currently scheduled for allogeneic stem cell transplant or high risk MDS according to IWG 2023
  • Patients who are or have been already treated with JAK inhibitors for VEXAS syndrome or another indication
  • Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 12 weeks prior to initiation of MMB
  • Previous history of Progressive Multifocal Leuko-encephalopathy (PML)
  • Active gastrointestinal conditions that may affect absorption
  • Known hypersensitivity to the study investigational medicinal product, the metabolites, or formulation excipients
  • Subjects with any other active malignancies are not eligible, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which subject has been disease-free for at least 3 years
  • Known infection with acute and chronic active HIV, HBV, HCV infections
  • Any medical or psychiatric condition not allowing the informed consent of the subject
  • Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy
  • No affiliation to a health insurance system
  • Patients who are unable to receive a starting daily dose of MMB of at least 100 mg

Where in France

  • Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
  • Chu Gabriel MontpiedClermont-Ferrand, FranceTaking people
  • Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
  • Centre Hospitalier Universitaire de LilleLille, FranceTaking people
  • Groupe Hospitalier Bretagne SudLorient, FranceTaking people
  • Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
  • Hopital Saint LouisParis, FranceTaking people
  • Hopital Saint AntoineParis Cedex 12, FranceTaking people
  • Centre Hospitalier Universitaire de BordeauxPessac, FranceTaking people
  • Hospices Civils de LyonPierre-Bénite, FranceTaking people
  • Centre Hospitalier Universitaire De RennesRennes Cedex 9, FranceTaking people
  • Oncopole Claudius RegaudToulouse, FranceTaking people
  • Centre Hospitalier Regional Universitaire De ToursTours Cedex 9, FranceTaking people

About the trial

What the trial wants to find out

Safety run-in :To determine the maximum tolerated dose (MTD) of momelotinib (MMB) in VEXAS patients Phase II : To determine clinical efficacy of MMB at 24 weeks on VEXAS related symptoms in UBA1 mutated and symptomatic patients refractory/dependent to steroids

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome
Plain-language title
Momelotinib tested in VEXAS syndrome, with or without myelodysplastic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 October 2026